Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.95
Sagaliam Acquisition Corp received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- late filing
- Rules
- 5250(c)(1)
Exact text from the filing
August 23, 2023 due to the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”) as a result of the Company’s failure to timely file its Annual Report on Form 10-Q for the fiscal quarter ended June 30, 2023 (the “ Form 10-Q ”). The Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “ SEC ”). The Notice states that since Nasdaq has not received the Company’s Form 10-Q for the period ended June 30, 2023, and because the Company remains delinquent in filing its Form 10-Q for the period ended
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Sagaliam Acquisition Corp entered into Business Combination Agreement with Enzolytics Inc., Virogentics Inc., Biogenysis Inc. (effective 2023-09-15).
- Action
- entry
- Agreement
- merger
- Counterparty
- Enzolytics Inc., Virogentics Inc., Biogenysis Inc.
- Effective
- 2023-09-15
Exact text from the filing
On September 15, 2023, Sagaliam Acquisition Corp., a Delaware corporation (“Sagaliam”), entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”) by and among Sagaliam Acquisition Corp. (“PubCo”), Enzolytics Inc. (OTC PK: ENZC), Virogentics Inc. (“VGEN”), and Biogenysis Inc. (“BGEN”).
View on SEC.gov